Form 483

King Pharmaceuticals LLC Form 483, 2012-12-13

FDA issued a Form 483 to King Pharmaceuticals LLC on 2012-12-13 with 6 public-safe observations.

483· Form 483 issued6 observations

King Pharmaceuticals LLC · Rochester, United States · Issued December 13, 2012

Overview

  • 6 public-safe observations are available for this inspection.
  • 5 structured CFR citations are represented.
  • 2 investigators are tied to this Form 483.

Inspectional observations

Each observation cites the regulation FDA found the firm out of compliance with.

13 Dec 2012
21 CFR 211.22(d)

Procedures not in writing, fully followed

Cited by Rebecca E Dombrowski, Sarah M Napier

13 Dec 2012
21 CFR 211.63

Equipment Design, Size and Location

Cited by Rebecca E Dombrowski, Sarah M Napier

13 Dec 2012
21 CFR 211.67(a)

Cleaning / Sanitizing / Maintenance

Cited by Rebecca E Dombrowski, Sarah M Napier

13 Dec 2012
21 CFR 211.67(b)

Written procedures fail to include

Cited by Rebecca E Dombrowski, Sarah M Napier

13 Dec 2012
21 CFR 211.67(b)

Written procedures not established/followed

Cited by Rebecca E Dombrowski, Sarah M Napier

Inspected site

KPKing Pharmaceuticals LLCRochester, United States

Inspection team

Cited regulations

CFR citations associated with this Form 483.

CitationWhat it coversCited
21 CFR 211.67(b)Cited across public-safe Form 483 observations2x
21 CFR 211.192Cited across public-safe Form 483 observations1x
21 CFR 211.22(d)Cited across public-safe Form 483 observations1x
21 CFR 211.63Cited across public-safe Form 483 observations1x
21 CFR 211.67(a)Cited across public-safe Form 483 observations1x

Source document

PDF
PDF available

Form 483 source document

The source document is available to authorized Atlas users.

Full 483 report

Get the verbatim text of all 6 observations

The source PDF and every observation in full, so your team sees exactly what was cited and how it was answered.

  • The site's full inspection history around this Form 483
  • Whether these citations escalated to a warning letter
  • The investigators involved and the citations they repeat elsewhere